CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more


Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Biomarker identifies risk of metastasis in uveal melanoma

PRAME biomarker’s link to ocular cancer metastasis could have ‘immediate clinical impact,’ say researchers


Scientists have discovered a biomarker that can be used to predict the risk of metastasis in patients with uveal melanoma.

Researchers studying the cancer at the University of Miami in the US found that melanomas with high levels of the biomarker PRAME were significantly more likely to develop metastasis than those with low levels of the molecule.

Uveal melanomas are classified as having either a high risk of metastasis (class 2) or a low risk (class 1). The team found that, of the latter class of cancers, those with low levels of the PRAME marker had a 0% risk of metastasis, whereas in those with high levels of the molecule this risk was 38%.

These results mean the scientists have successfully identified a way to easily distinguish between melanomas that are likely to spread to other parts of the body and those that are not.

Lead author and University of Miami eye cancer expert, Dr J. William Harbour, said that the results had important implications for the treatment of ocular cancer.

Dr Harbour commented: “These findings could have immediate clinical impact. The data imply that patients with class 1 uveal melanomas with increased PRAME expression should be managed differently than patients with class 1 uveal melanomas without PRAME expression. They should be monitored more closely for metastatic disease and they should be considered for clinical trials of adjuvant therapy.”

Eye cancers are fairly rare in the UK, with fewer than 500 cases diagnosed each year. Of these, uveal melanoma is the most common.

Depending on the stage at which the disease is detected, survival rates for ocular cancers in the UK vary between 84% and 47%.

The researchers now plan to undertake a prospective multi-centre study to fully validate their findings.

The research was published this week in the journal Clinical Cancer Research.

Image credit: Wikimedia Commons